Mildronate: An antiischemic drag for neurological indications

CNS Drug Reviews

Volumn 11, Issue 2, 2005, Pages 151-168

  Sjakste, Nikolajs ^a,b   Gutcaits, Aleksandrs ^b   Kalvinsh, Ivars ^b  

^a UNIVERSITY OF LATVIA   (Latvia)

^b LATVIAN INSTITUTE OF ORGANIC SYNTHESIS   (Latvia)

Author keywords

Antiischemic drugs; Cerebral circulation; Mildronate; Nitric oxide; Butyrobetaine hydroxylase inhibitors

Indexed keywords

CHOLINERGIC RECEPTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GAMMA BUTYROBETAINE; MELDONIUM; MILDRONATE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PLACEBO; QUATERINE; 3 (2,2,2 TRIMETHYLHYDRAZINE)PROPIONATE; 3-(2,2,2-TRIMETHYLHYDRAZINE)PROPIONATE; CARDIOVASCULAR AGENT; KETONE BODY; METHYLHYDRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ASTHENIA; BRAIN CIRCULATION; BRAIN DYSFUNCTION; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM FUNCTION; DIZZINESS; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; ENZYME ACTIVATION; FATTY ACID OXIDATION; HEART MUSCLE ISCHEMIA; HUMAN; MOOD; MOTOR DYSFUNCTION; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; OXYGEN CONSUMPTION; RABBIT; REVIEW; TOXICITY TESTING; VASCULAR ENDOTHELIUM; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; DRUG SCREENING; ISCHEMIA; METABOLISM; METHODOLOGY; NEUROPHARMACOLOGY; TOXICOLOGY;

ANIMALS; CARDIOVASCULAR AGENTS; DRUG EVALUATION; HUMANS; ISCHEMIA; KETONE BODIES; METHYLHYDRAZINES; MODELS, BIOLOGICAL; NEUROPHARMACOLOGY; NITRIC OXIDE; TOXICOLOGY;

EID: 24644486441     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2005.tb00267.x     Document Type: Review

References (71)

1. Abeuov BA, Raimkulov BN, Mitrokhin DA, et al. Condition of the higher brain functions in patients with dyscirculatory encephalopathy treated with mildronate. Meditsina 2004;2:78-81 (in Russian).
2. Beketov AI, Mametova AN, Polevik IV, Sapegin ID. Comparative characteristics of cerebrovascular protective effects of mildronate, riboxine, and their combination during modeling of cerebral hemodynamics disturbance. Éksp Klin Farmakol 2000;63:18-21 (in Russian).
3. Belitskii GA, Kalvinysh IIa, Anisimov VN, Khovanova EM, Ugvinenko EG, Tolcheev IuD. Absence of mutagenic and carcinogenic properties in mildronate. Vopr Onkol 1999;45:279-282 (in Russian).
4. Blium IaB, Babeniuk Yu D, Kalvin'sh IIa, Bratus NI, Kucherenko NE. Influence of the Mildronate on intensity of the ADP-ribosylation of chromatin proteins. Latv Zinatnu Akad Vestis 1990;8:120-125 (in Russian).
5. Blium Ia. B, Kalvin'sh IIa, Kucherenko NE, Lukevits EIa. Effect of quaterin and S-methylmethionine on the intensity of chromatin protein methylation. Voen-Med Zh 1987;59:18-24 (in Russian).
6. Blium IaB, Kalvin'sh IIa, Kucherenko NE, Lukevits EIa. Stimulation with quaterin of DNA replication and repair. Voen-Med Zh 1988;60:19-23 (in Russian).
7. Blium IaB, Verbovikova EA, Kalvin'sh IIa, Bratus NI, Babeniuk YuD, Kucherenko NE. Influence of the trimethylhydrazine analogue of gamma-butyrobetaine - Mildronate - on the pre-mRNA biosynthesis. Latv Zinatnu Akad Vestis 1990;10:105-109 (in Russian).
8. Chiba S, Akahane K, Furukawa Y, Karasawa Y. Direct chronotropic and inotropic effects of mildronate using cross-circulated dog atrial and ventricular preparations. Jpn Heart J 1989;30:743-750.
9. Dambrova M, Chlopicki S, Liepinsh E, et al. The methylester of gamma-butyrobetaine, but not gamma-butyrobetaine itself, induces muscarinic receptor-dependent vasodilatation. Naunyn Schmiedeberg's Arch Pharmacol 2004;369:533-539.
10. Dambrova M, Liepinsh E, Kalvinsh I. Mildronate: Cardioprotective action through carnitine-lowering effect. Trends Cardiovasc Med 2002;12:275-279.
11. Degrace P, Demizieux L, Gresti J, et al. Fatty acid oxidation and related gene expression in heart depleted of carnitine by mildronate treatment in the rat. Mol Cell Biochem 2004;258:171-182.
12. Dziak LA, Golik VA. Use of mildronate for the treatment of patients with circulatory encephalopathy against a background of stenosis of major arteries of the head. Lik Sprava 2003;5-6:98-101 (in Russian).
13. Dzintare M. Changes of concentration of nitric oxide in tissues under action of different pharmacological agents. Summary of a Doctoral Thesis. Riga: University of Latvia, 2004;1-76.
14. Dzintare M, Baumane L, Meirena D, Lauberte L, Kalvinsh I, Sjakste N. Involvement of nitric oxide production in the mildronate mechanism of action. Pharmacol Rev Commun 2002;12:163-170.
15. Enina G, Timofeeva T, Egere D, Majore I. Medicinal effects and indications to mildronate application in neuroangiologic practice. Éksp Klin Farmakoter (Riga) 1991;Issue 19:164-171 (in Russian).
16. Frantsuzova SB., Jatsetnko VP, Zotov AS, Antonenko LI, Arshinnikova LL. Pharmacodynamics of mildronate: A review. Zh Akad Med Nauk Ukr 1997;3:612-624 (in Russian).
17. Gaidar BV, Parfenov VE, Vainshtein GB. Ways to optimize the cerebral circulation during extreme actions on the brain. Fiziol Zh Sechenova 1989;75:1568-1575 (in Russian).
18. Galland S, Le Borgne F, Guyonnet D, Clouet P, Demarquoy J. Purification and characterization of the rat liver gamma-butyrobetaine hydroxylase. Mol Cell Biochem 1998;178:163-168.
19. Georges B, Le Borgne F, Galland S, et al. Carnitine transport into muscular cells. Inhibition of transport and cell growth by mildronate. Biochem Pharmacol 2000;59:1357-1363.
20. Germane S. Experimental study of mildronate effect on the central nervous system. Èksp Klin Farmakoter (Riga) 1991;Issue 19:44-50 (in Russian).
21. Germane S., Berzina D. Effect of mildronate on catecholamine level and somatic manifestations in white rats organs under stress. Éksp Klin Farmakoter (Riga) 1991;Issue 19:51-56 (in Russian).
22. 2+ uptake activity in rats with congestive heart failure following myocardial infarction. Mol Cell Biochem 2000;209:39-46.
23. Hayashi Y, Muranaka Y, Kirimoto T, Asaka N, Miyake H, Matsuura N. Effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor, on tissue carnitine and lipid levels in rats. Biol Pharm Bull 2000;236: 770-773.
24. Heidemanis K, Balcere I, Kalvinsh I. Mildronate-plasma membrane interaction mechanisms. Latv Zinatnu Akad Vestis 1990;11:108-115.
25. Herrera MD, Bueno R, De Sotomayor MA, Perez-Guerrero C, Vazquez CM, Marhuenda E. Endothelium-dependent vasorelaxation induced by L-carnitine in isolated aorta from normotensive and hypertensive rats. J Pharm Pharmacol 2002;54:1423-1427.
26. Hosein EA, Kato A, Vine E, Hill AM. The identification of acetyl-L-carnitylcholine in rat brain extracts and the comparison of its cholinomimetic properties with acetylcholine. Can J Physiol Pharmacol 1970;48: 709-722.
27. Hosein EA, Proulx P. Acetylcholine-like activity in subcellular particles isolated from rat brain. Arch Biochem Biophys 1964;106:267-274.
28. Hwang YC, Bakr S, Ramasamy R, Bergmann SR. Relative importance of enhanced glucose uptake versus attenuation of long-chain acyl carnitines in protecting ischemic myocardium. Coronary Artery Dis 2002; 136:313-318.
29. Kagan TI, Simkhovich BZ, Kalvinysh IIa, Lukevits EIa. Study of the effect of an inhibitor of carnitine-dependent metabolism of mildronate on the oxidation of fatty acids in the liver mitochondria of intact rats. Vopr Med Khimii 1991;37:44-46 (in Russian).
30. Kalvinsh I. Synthesis and pharmacological activity of a new bioregulator mildronate. Éksp Klin Farmakoter (Riga) 1991;Issue 19:7-14 (in Russian).
31. Kalvinsh I, Veveris M. Pharmaceutical composition for treating cardiovascular diseases containing 3-(2,2, 2-trimethylhydrazinium) propionate and gamma-butyrobetaine. US Pat. 5,859,056, Int. Cl.6 A61K3/205, 01/12/1999.
32. Karpov RS, Dudko VA, Shipulin VM, et al. The clinical instrumental evaluation of treatment efficacy in patients with concomitant atherosclerosis of the coronary, cerebral and peripheral arteries. Ter Arkh 1991;634:90-93 (in Russian).
33. Kirimoto T, Nobori K, Asaka N, Muranaka Y, Tajima K, Miyake H. Beneficial effect of MET-88, a gamma-butyrobetaine hydroxylase inhibitor, on energy metabolism in ischemic dog hearts. Arch Int Pharmacodyn Ther 1996;331:163-178.
34. Klimkane L, Koronova Zh, Kalvinsh I, Zakenfelds G. The effect of mildronate on cancerogenesis and on the growth of transplanted tumours. Proc Latv Acad Sci B 1992;2:54-59 (in Latvian).
35. Kuwajima M, Harashima H, Hayashi M, et al. Pharmacokinetic analysis of the cardioprotective effect of 3-(2,2,2-trimethylhydrazinium) propionate in mice: Inhibition of carnitine transport in kidney. J Pharmacol Exp Ther 1999;289:93-102.
36. Lerch R, Tamm C, Papageorgiou I, Benzi RH. Myocardial fatty acid oxidation during ischemia and reperfusion. Mol Cell Biochem 1992;116:103-109.
37. Logai IM, Guseva OG, Kalvin'sh IIa. The use of lysosomotropic preparations in treating severe experimental chemical eye burns. Oftal'mol Zh 1989;8:497-500 (in Russian).
38. Lychkova AE, Savchuk VI, Smirnov VM. Experimental gastric ulcer: Gastro- and duodenoprotective effects of sibusol. Bull Exp Biol Med 2004;137:34-36.
39. Logunova LV, Sutulov YuI. Studies on mildronate effect on the development and healing of stress ulcer stomach injuries in the experiment. Éksp Klin Farmakoter (Riga) 1992;Issue 20:82-91 (in Russian).
40. Meerson FZ, Abdikaliev NA, Kalvin'sh IIa, Vovk VI. Bioelectrical mechanism of the anti-arrhythmia effect of a synthetic acetylcholine analogue EDIHYP. Kardiologiya 1995;31:52-55 (in Russian).
41. Moskalenko YE, Gaidar BV, Parfenov VE. Strategy for pharmacological correction of cerebral ischemia: Systemic approaches. In: Kriegslein J, Oberpichler-Schwenk H, Eds. Pharmacolgy of cerebral ischemia. Stuttgart: Wissenschaftliche Verlagsgesselschaft mbH, 1999.
42. Okunevich IV, Ryzhenkov VE. Anti-atherosclerotic action of mildronate in experiment. Patol Fiziol Éksp Ter 2002;2:24-27 (in Russian).
43. Orbidane O, Meirena D, Pugovics O, et al. Gamma-butyrobetaine esterase activity in rat blood serum. Proc LatvAcadSci B 2004;58:98-102.
44. Pcheliakov VF, Arnautova LV. Reparative post-traumatic regeneration of the rabbit cornea after administration of quaterin. Oftal'mol Zh 1987;6:369-373 (in Russian).
45. Petersone I, Veveris M, Berzina D, Kalnciema V, Lepika V, Eglite I. Acute and chronic toxicity of mildronate. Éksp Klin Farmakoter (Riga) 1991;Issue 19:67-71 (in Russian).
46. Ratunova TM, Bauman VR, Kalvin'sh IIa. The cardioprotective action of camitine and its structural analog 3-(2,2,2-trimethylhydrazine)propionate on cardiac energy metabolism in experimental occlusion of the coronary artery in rats. Farmakol Toksikol 1989;52:24-27 (in Russian).
47. Rugaja Z, Kagan T, Majore A, et al. Effects of mildronate on experimental hepatic carcinogenesis. Latv Zinatnu Akad Vestis 1990;6:122-129 (in Russian).
48. Rupp H, Zarain-Herzberg A, Maisch B. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz 2002;27:621-636.
49. Salnikov SN. Cytoprotector mildronate and cerebral oxygenation. Appendix for the Information edition of the Grindex for physicians, pharmaceutists and specialists. Vol. 3. Riga: 2002;2-4.
50. Shutenko ZhV, Meirena DV, Kagan TI, Sjakste NI, Kalvin'sh IIa. Mildronate: Mechanisms of action, perspective for pathology correction. Khim-Pharm Zh 1995;29:13-17 (in Russian).
51. Shutenko ZhV, Priedena IA, Mezhapuke RIa, Simkhovich BZ, Kalvin'sh IIa, Lukevits EIa. The effect of the carnitine biosynthesis inhibitor mildronate on the lipid metabolic indices of rats. Farmakol Toksikol 1991;542:55-56 (in Russian).
52. Shutenko ZhV, Simkhovich BZ, Meirena DV, Kalvin'sh IIa, Lukevits EIa. Regulation of carnitine-dependent metabolism of fatty acids in the rat myocardium using 3-(2,2,2-trimethylhydrazinium) propionate. Vopr Med Khimii 1989;352:59-64 (in Russian).
53. Simkhovich BZ. Mildronate. Cardioprotector. A remedy increasing work efficiency. Riga: Academy of Sciences of the Latvian SSSR, 1988:1-4 (in Russian).
54. Simkhovich BZ, Meirena DV, Khagi KhB, Kalvin'sh IIa, Lukevits EIa. Effect of a new structural analog of gamma-butyrobetaine-3-(2,2,2-trimethylhydrazine) propionate (THP) on carnitine level, carnitine-dependent fatty acid oxidation and various indices of energy metabolism in the myocardium. Vopr Med Khimii 1986;324:72-76 (in Russian).
55. Simkhovich BZ, Meirena DV, Khagi KhB, Kalvin'sh IIa, Lukevits EIa. Biochemical characteristics of the anti-ischemic action of the new structural analog of gamma-butyrobetaine 3-(2,2,2-trimethylhydrazine)propionate. Farmakol Toksikol 1987;50:100-104 (in Russian).
56. Simkhovich BZ, Shutenko ZV, Meirena DV, et al. 3-(2,2,2- Trimethylhydrazinium) propionate (THP) - a novel gamma-butyrobetaine hydroxylase inhibitor with cardioprotective properties. Biochem Pharmacol 1988;37:195-202.
57. Simkhovich BZ, Vitolinia RO, Stivrinia MI, Shutenko ZhV, Meirena DV. Prevention of ischemic myocardial damage by reducing the intracellular free carnitine level. Kardiologiya 1987;27:85-88 (in Russian).
58. Sizova EN, Tsirkin VI, Dvorianskii SA. The role of endogenous modulators of chemoreactivity in the regulation of coronary blood flow. Ross Fiziol Zh Sechenova 2002;88:856-864 (in Russian).
59. Sjakste N, Baumane L, Boucher JL, et al. Effects of gamma-butyrobetaine and mildronate on nitric oxide production in lipopolysaccharide-treated rats. Basic Clin Pharmacol Toxicol 2004;94:46-50.
60. Sjakste N, Kleschyov AL, Boucher JL, et al. Endothelium- and nitric oxide-dependent vasorelaxing activities of gamma-butyrobetaine esters: Possible link to the antiischemic activities of mildronate. Eur J Pharmacol 2004;495:67-73.
61. Sjakste N, Meirena D, Dzene A, Mebapuie R, Ignatovich L, Lukevics E. Modifications of the genome expression by several novel drugs. Exp Biol (Vilnius) 1992;26:3-4.
62. Spaniol M, Brooks H, Auer L, et al. Development and characterization of an animal model of carnitine deficiency. Eur J Biochem 2001;268:1876-1887.
63. Suslina ZA, Fedorova TN, Maksimova MIu, Kim EK. Antioxidant activity of mildronate and L-carnitine in the treatment of patients with cerebrovascular diseases. Éksp Klin Farmakol 2003;66:32-35 (in Russian).
64. Thomizek WD, Strack E, Lorenz J. Über den Einfluß einiger Derivate aliphatischen Trimethylbetaine auf die Acetylcholine-esterase und über die Hydrolyse von Betainestern. Acta Biol Med Germ 1963;11:353-355 (in German).
65. Tsoko M, Beauseigneur F, Gresti J, Demarquoy J, Clouet P. Hypolipidaemic effects of fenofibrate are not altered by mildronate-mediated normalization of carnitine concentration in rat liver. Biochimie 1998;80: 943-948.
66. Tsoko M, Beauseigneur F, Gresti J, et al. Enhancement of activities relative to fatty acid oxidation in the liver of rats depleted of L-carnitine by D-carnitine and a gamma-butyrobetaine hydroxylase inhibitor. Biochem Pharmacol 1995;49:1403-1410.
67. Vaz FM, Wanders RJA. Carnitine biosynthesis in mammals. Biochem J 2002;361:417-429.
68. Vetra A, Shefere M, Skarda I, Matveja L, Kalvinsh I. Significance of mildronate for improvement of results of early rehabilitation results of neurological patients. Latvijas Arstu Zurnals 1999;12:33-37 (in Latvian).
69. Vinichuk SM. The efficacy of the mildronate treatment of patients with ischemic stroke. Vrach Delo 1991;7:77-79 (in Russian).
70. 2+-ATPase and hexokinase type I in rat hearts with myocardial infarction. Basic Res Cardiol 2000;95:343-348.
71. Yoshisue K, Yamamoto Y, Yoshida K, et al. Pharmacokinetics and biological fate of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate (MET-88), a novel cardioprotective agent, in rats. Drug Metab Dispos 2000; 28:687-694.